Our agents specifically recognize unique biomarkers only present in the tumor microenvironment.
Each agent is easily modified for tumor diagnosis, fluorescent guided surgery, specific MRI and PET imaging or targeted tumor therapeutics.
Therapeutics are targeted for brain tumors, melanoma, breast, ovarian, prostate and lung cancer.
Neo-001 Technology
Chief Scientific Officer
Chief Executive Officer
Chief Operating Officer
Wellington, Ohio 44090, United States
Open today | 09:00 am – 05:00 pm |
Copyright © 2024 NeoIndicate - All Rights Reserved.
Powered by GoDaddy Website Builder